Abstract
Importance The decline of anti-SARS-COV-2 antibody titers has been documented. It is not clear whether the antibodies are persistent in infected individuals who had no symptoms. Serial serological tests on the same individuals can provide insights into the population-level prevalence and dynamic patterns of seropositivity against COVID-19 infection.
Objective To assess changes in COVID-19 seroprevalence and the persistence among the asymptomatic working population in Tokyo from May 2020 to December 2020, spanning from the second wave to the third wave of COVID19 through serial testing on the same individuals.
Design We conducted a cohort observational study about SARS-COV-2 seropositivity on the same individuals with no COVID-19 symptoms from May 26 to December 15, 2020. Six hundred fifteen healthy volunteers (mean ± SD 40.8 ± 10.0, range 19 - 69; 45.7 % female) from 1877 office workers were initially enrolled from 11 disparate locations across Tokyo. Participants having fever, cough, or shortness of breath at the time of testing were excluded. Fingertip blood was applied onto the cassette of a COVID19 IgM/IgG rapid test kit to detect antibodies. We compared two test results with the same kits approximately one month apart for the self-reference to validate the positive test results. Initial two tests were performed weekly from May 26 to August 25. Those who had positive test results either at the first or second test were offered the follow-up test on Dec 8 or 15, 2020. An outside ethical committee reviewed and approved the protocol.
Participants Healthy office workers from 11 disparate locations (1877 employees in total) across Tokyo volunteered to the study. Participants having fever, cough, or shortness of breath at the time of testing were excluded.
Main Outcome(s) and Measure(s): Seropositivity rate (SPR) was calculated by pooled data from each two-week window from May 26 to August 25. Either IgM or IgG positivity was defined as seropositive. Changes in immunological status against SARS-CoV-2 were determined by comparing results between two tests a month apart obtained from the same individual. A Follow-up test was offered to the seropositive individuals on December 8 or 15.
Results Six hundred fifteen healthy volunteers (mean + SD 40.8 + 10.0; range 19 - 69; 45.7 % female) received at least one test. Seropositivity rate (SPR) increased from 5.8 % to 46.8 % during the second wave. The most dramatic increase in SPR occurred in late June and early July, paralleling the rise in daily confirmed cases within Tokyo, which peaked on August 4. Out of the 350 individuals (mean + SD 42.5 + 10.0; range 19 - 69; 46.0 % female) who completed the initial two tests, 152 participants were found to be seropositive at either the first or second test. Out of 152 seropositive individuals, 74 participants (52%: women, median age: 44 years, range: 23 – 69 years) underwent the third test. The interval between the initial positive results and the third test was approximately four months (mean ± S.D. 120 ± 17 days). Thirty participants (40.5 %) became seronegative at the third test on December 8 or 15.
Conclusions and Relevance COVID-19 infection may have spread widely across the general population of Tokyo despite the quite low fatality rate during the second wave. Given the temporal correlation between the rise in seropositivity and peaking in reported COVID-19 cases that occurred without a shut-down, Tokyo might achieve herd immunity temporally at the second wave. Substantial reduction of the seropositivity among asymptomatic individuals in four months in December may explain why Tokyo had the third wave, the resurgence of COVID19 is occurring every 3 to 4 months, and the herd immunity strategy has not succeeded.
Summary
Serial testing of antibodies in the same individuals with a month apart provided self-reference to validate the results for asymptomatic individuals.
The weekly seropositivity rate among the participants increased from 5.8 % (before) to 46.8 % (during) in parallel to the increase of confirmed case number of COVID-19 during the second wave of COVID-19 in Tokyo.
Participants who had positive results in the tests a month apart had follow-up test four months after the positive results.
Among the seropositive participants, 40.5 % turned seronegative at the follow-up test.
The temporal correlation between the rise in the seropositivity and the decrease in reported COVID-19 cases without imposing lockdown measures during the second wave may indicate Tokyo temporarily achieved herd immunity.
Substantial reduction of seroprevalence in the asymptomatic population in four months may explain why the third wave hit Tokyo, the resurgence of COVID19 is occurring every 3 to 4 months, and the herd immunity strategy has not succeeded.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical committee at the Tokyo Cancer Clinic
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
upon the request
